329 related articles for article (PubMed ID: 26914985)
1. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
Martin LJ; Koegl M; Bader G; Cockcroft XL; Fedorov O; Fiegen D; Gerstberger T; Hofmann MH; Hohmann AF; Kessler D; Knapp S; Knesl P; Kornigg S; Müller S; Nar H; Rogers C; Rumpel K; Schaaf O; Steurer S; Tallant C; Vakoc CR; Zeeb M; Zoephel A; Pearson M; Boehmelt G; McConnell D
J Med Chem; 2016 May; 59(10):4462-75. PubMed ID: 26914985
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.
Zheng P; Zhang J; Ma H; Yuan X; Chen P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1391-1404. PubMed ID: 30824168
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
Yang Y; Chen P; Zhao L; Zhang B; Xu C; Zhang H; Zhou J
Bioorg Med Chem; 2021 Jan; 29():115857. PubMed ID: 33191086
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.
Hohmann AF; Martin LJ; Minder JL; Roe JS; Shi J; Steurer S; Bader G; McConnell D; Pearson M; Gerstberger T; Gottschamel T; Thompson D; Suzuki Y; Koegl M; Vakoc CR
Nat Chem Biol; 2016 Sep; 12(9):672-9. PubMed ID: 27376689
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains.
Karim RM; Chan A; Zhu JY; Schönbrunn E
J Med Chem; 2020 Mar; 63(6):3227-3237. PubMed ID: 32091206
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.
Crawford TD; Vartanian S; Côté A; Bellon S; Duplessis M; Flynn EM; Hewitt M; Huang HR; Kiefer JR; Murray J; Nasveschuk CG; Pardo E; Romero FA; Sandy P; Tang Y; Taylor AM; Tsui V; Wang J; Wang S; Zawadzke L; Albrecht BK; Magnuson SR; Cochran AG; Stokoe D
Bioorg Med Chem Lett; 2017 Aug; 27(15):3534-3541. PubMed ID: 28606761
[TBL] [Abstract][Full Text] [Related]
9. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
Krämer KF; Moreno N; Frühwald MC; Kerl K
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
[TBL] [Abstract][Full Text] [Related]
10. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
Yoo M; Yoo M; Kim JE; Lee HK; Lee CO; Park CH; Jung KY
Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
[TBL] [Abstract][Full Text] [Related]
13. Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.
Crawford TD; Tsui V; Flynn EM; Wang S; Taylor AM; Côté A; Audia JE; Beresini MH; Burdick DJ; Cummings R; Dakin LA; Duplessis M; Good AC; Hewitt MC; Huang HR; Jayaram H; Kiefer JR; Jiang Y; Murray J; Nasveschuk CG; Pardo E; Poy F; Romero FA; Tang Y; Wang J; Xu Z; Zawadzke LE; Zhu X; Albrecht BK; Magnuson SR; Bellon S; Cochran AG
J Med Chem; 2016 Jun; 59(11):5391-402. PubMed ID: 27219867
[TBL] [Abstract][Full Text] [Related]
14. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.
Crawford TD; Romero FA; Lai KW; Tsui V; Taylor AM; de Leon Boenig G; Noland CL; Murray J; Ly J; Choo EF; Hunsaker TL; Chan EW; Merchant M; Kharbanda S; Gascoigne KE; Kaufman S; Beresini MH; Liao J; Liu W; Chen KX; Chen Z; Conery AR; Côté A; Jayaram H; Jiang Y; Kiefer JR; Kleinheinz T; Li Y; Maher J; Pardo E; Poy F; Spillane KL; Wang F; Wang J; Wei X; Xu Z; Xu Z; Yen I; Zawadzke L; Zhu X; Bellon S; Cummings R; Cochran AG; Albrecht BK; Magnuson S
J Med Chem; 2016 Dec; 59(23):10549-10563. PubMed ID: 27682507
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
17. Research progress of selective small molecule bromodomain-containing protein 9 inhibitors.
Hui M; Jian Z; Peiyuan Z; Zhenwei W; Huibin Z
Future Med Chem; 2018 Apr; 10(8):895-906. PubMed ID: 29620420
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
[TBL] [Abstract][Full Text] [Related]
19. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
Zhao L; Wang Y; Cao D; Chen T; Wang Q; Li Y; Xu Y; Zhang N; Wang X; Chen D; Chen L; Chen YL; Xia G; Shi Z; Liu YC; Lin Y; Miao Z; Shen J; Xiong B
J Med Chem; 2015 Feb; 58(3):1281-97. PubMed ID: 25559428
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer.
Jiang W; Wang X; Shu C; Hou Q; Yang K; Wu X
Bioorg Chem; 2022 Feb; 119():105575. PubMed ID: 34995979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]